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Mesenchymal stromal cells inhibit 
NLRP3 inflammasome activation 
in a model of Coxsackievirus 
B3-induced inflammatory 
cardiomyopathy
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Irene Müller1,2, Fengquan Dong1, Konstantinos Savvatis1, Jochen Ringe1,4,  
Carsten Tschöpe1,2,5 & Sophie Van Linthout1,2,5
Inflammation in myocarditis induces cardiac injury and triggers disease progression to heart 
failure. NLRP3 inflammasome activation is a newly identified amplifying step in the pathogenesis 
of myocarditis. We previously have demonstrated that mesenchymal stromal cells (MSC) are 
cardioprotective in Coxsackievirus B3 (CVB3)-induced myocarditis. In this study, MSC markedly 
inhibited left ventricular (LV) NOD2, NLRP3, ASC, caspase-1, IL-1β, and IL-18 mRNA expression in 
CVB3-infected mice. ASC protein expression, essential for NLRP3 inflammasome assembly, increased 
upon CVB3 infection and was abrogated in MSC-treated mice. Concomitantly, CVB3 infection in vitro 
induced NOD2 expression, NLRP3 inflammasome activation and IL-1β secretion in HL-1 cells, which 
was abolished after MSC supplementation. The inhibitory effect of MSC on NLRP3 inflammasome 
activity in HL-1 cells was partly mediated via secretion of the anti-oxidative protein stanniocalcin-1. 
Furthermore, MSC application in CVB3-infected mice reduced the percentage of NOD2-, ASC-, p10- 
and/or IL-1β-positive splenic macrophages, natural killer cells, and dendritic cells. The suppressive 
effect of MSC on inflammasome activation was associated with normalized expression of prominent 
regulators of myocardial contractility and fibrosis to levels comparable to control mice. In conclusion, 
MSC treatment in myocarditis could be a promising strategy limiting the adverse consequences of 
cardiac and systemic NLRP3 inflammasome activation.
Coxsackievirus B3 (CVB3) infection is a predominant cause of viral myocarditis, which can induce sudden 
death in young adults or progress to dilated cardiomyopathy. Main characteristics of viral myocarditis are 
a local and systemic inflammatory response. While inflammatory processes are a necessary immune defense 
for ultimate viral elimination and healing, inflammation induces cardiac injury and represent a major mech-
anism in the pathogenesis of myocarditis1. The innate immunity is the first line of defense, which senses via 
pattern-recognition receptors (PRRs) signals of “danger,” including pathogen-associated molecular patterns 
(PAMPs) and host-derived signals of cellular stress, known as danger-associated molecular patterns (DAMPs)2,3. 
One of the four main classes of PRRs are nucleotide-binding oligomerization domain (NOD)-like receptors 
(NLRs), which are intracellular receptors and can be assembled into larger structures, termed inflammasomes4. 
NOD2 is a cytoplasmatic PRR member of the NLR family, which recognizes CVB35, plays an important role 
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in the innate immune response and is associated with cardiac injury by exacerbation of inflammation and car-
diac remodeling6. NOD2 activates (NOD)-like receptor pyrin domain-containing 3 (NLRP3) inflammasome 
and IL-1β processing and secretion4, primarily on phagocytic antigen-presenting cells such as macrophages and 
Figure 1. Mesenchymal stromal cells abrogate Coxsackievirus B3-induced expression of NOD2 and NLRP3 
inflammasome components and products in the heart. Bar graphs represent the mean ± SEM of (A) NOD2, (B) 
NLRP3, (C) ASC, (D) Caspase 1, (E) IL-1β and (F) IL-18 mRNA expression in the LV of control, CVB3, control 
MSC, and CVB3 MSC mice, as indicated, with n = 5–6/group and *p < 0.05 and **p < 0.01. (G) Bar graphs 
represent the mean ± SEM of a quantitative analysis ASC positive area in the heart of control, CVB3, control 
MSC, and CVB3 MSC mice, as indicated, with n = 4–6/group and ***p < 0.001. (H) ASC expression in LV of 
control mice receiving PBS (upper left panel) or MSC (lower left panel), or of CVB3 infected mice receiving PBS 
(upper right panel) or MSC (lower right panel), detected by immunohistochemistry at a magnification of ×100. 
Bar graphs represent the mean ± SEM of (I) LV caspase 1 activity represented as absorbance at 405 nm and 
(J) IL-1β protein expression, depicted as pg IL-1ß per µg LV protein, determined in the LV of control, CVB3, 
control MSC, and CVB3 MSC mice, with n = 5–6/group.
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dendritic cells (DCs). Activated NLRP3 interacts with the adapter apoptosis-associated speck-like protein con-
taining a C-terminal caspase recruitment domain (ASC), resulting in recruitment of pro-caspase-1 and induction 
of auto-cleavage of caspase-14. Caspase-1 is known as the inflammatory caspase essential in the maturation of the 
two highly pro-inflammatory interleukins (IL)−1 family cytokines: IL-1β and IL-18, known to exacerbate the 
Figure 2. Mesenchymal stromal cells suppress NOD2 expression and NLRP3 inflammasome activation in 
Coxsackievirus B3-infected cardiomyocytes. Bar graphs represent the mean ± SEM of (A) NOD2+/DiO+, (B) 
ASC+/DiO+, (C) Caspase 1+/DiL+, (D) pro-IL-1β+/DiO+ and (E) IL-1β+/DiO+ cells cells depicted as the % of 
gated cells of basal or MSC (open bars) or CVB3-infected (closed bars) HL-1 cardiomyocytes with or without 
MSC, as indicated with n = 5–6/group, *p < 0.05, **p < 0.01 and ***p < 0.001.
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inflammatory responses and induce cardio-depressive effects and cardiac remodeling7–9. The NLRP3 inflammas-
ome has been identified as a central player in the development of heart diseases. NLRP3 inflammasome activation 
in resident cardiomyocytes and fibroblasts leads to myocardial dysfunction, while inflammasome inhibition lim-
its inflammation and myocardial fibrosis10,11.
CVB3 infection induces NLRP3 inflammasome activation in vitro and in vivo, which inhibition has been 
shown to significantly alleviate the severity of CVB3-induced myocarditis and to improve cardiac function12. 
The clinical relevance of NOD2 and NLRP3 in CVB3-induced myocarditis follows from recent own find-
ings in CVB3-postive myocarditis patients which show that cardiac NOD2 and NLRP3 expression drops in 
CVB3-positive patients who eliminated the virus and improved cardiac function over time13. Therefore, inhibi-
tion of NLRP3 inflammasome activation or IL-1β may be a valuable therapeutic strategy to limit the inflamma-
tory response, which high intensity is a clear negative prognostic marker14.
Mesenchymal stromal cells (MSC) are effective immunomodulators of the immune responses15–17. We 
have demonstrated that intravenous (i.v.) MSC application has a cardioprotective effect in CVB3-induced 
Figure 3. Mesenchymal stromal cells inhibit Coxsackievirus B3-induced NOD2 expression in macrophages, 
natural killer cells, and dendritic cells. (A) Bar graphs represent the mean ± SEM of NOD2-positive splenocytes 
in control mice (open bar) and CVB3-infected mice (closed bar) injected with PBS or MSC, expressed as the 
percentage of total MNCs, with n = 8–9/group. The right panel shows dot plots of NOD2 positive splenocytes 
of control, CVB3, control MSC, and CVB3 MSC mice, as indicated. (B) Bar graphs represent the mean ± SEM 
of F4/80+/NOD2+ in control mice (open bar) and CVB3-infected mice (closed bar) injected with PBS or MSC, 
expressed as the percentage of total MNCs, with n = 8–9/group and **p < 0.01. The right panel shows dot plots 
of F4/80+/NOD2+- positive splenocytes of control, CVB3, control MSC, and CVB3 MSC mice, as indicated. 
(C) Bar graphs represent the mean ± SEM of CD49b+/NOD2+ in control mice (open bar) and CVB3-infected 
mice (closed bar) injected with PBS or MSC, expressed as the percentage of total MNCs, with n = 8–9/group 
and **p < 0.01. The right panel shows dot plots of CD49b+/NOD2+-positive splenocytes of control, CVB3, 
control MSC, and CVB3 MSC mice, as indicated. (D) Bar graphs represent the mean ± SEM of CD11c+/NOD2+ 
in control mice (open bar) and CVB3-infected mice (closed bar) injected with PBS or MSC, expressed as the 
percentage of total MNCs, with n = 8–9/group and **p < 0.01. The right panel shows dot plots of CD11c+/
NOD2+-positive splenocytes of control, CVB3, control MSC, and CVB3 MSC mice, as indicated.
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inflammatory cardiomyopathy since MSC cannot be infected with CVB3, exert anti-viral effects, reduce 
CVB3-associated cardiomyocyte apoptosis, myocardial fibrosis, inflammation, improve left ventricle (LV) func-
tion and induce prominent systemic immunomodulation18,19.
Taking into account that the NLRP3 inflammasome is known to play a crucial role in the pathogenesis of 
CVB3-induced myocarditis and MSC have been shown to inhibit NLRP3 inflammasome activation in mac-
rophages20, the aim of the present study was to evaluate the effect of i.v. MSC application on NLRP3 inflam-
masome activation in murine CVB3-induced myocarditis. We could demonstrate that MSC potently inhibit the 
NLRP3 inflammasome activation in the heart and mediate systemic immunoregulation via abrogating NLRP3 
inflammasome activation and IL-1β secretion in cells of the innate immune system, which could interrupt the 
inflammatory process amplification and subsequently diminish the adverse cardiac inflammation and dysfunc-
tion following myocardial injury.
Figure 4. Mesenchymal stromal cells inhibit Coxsackievirus B3-induced ASC activation in macrophages, 
natural killer cells, and dendritic cells. (A) Bar graphs represent the mean ± SEM of ASC-positive splenocytes 
in control mice (open bar) and CVB3-infected mice (closed bar) injected with PBS or MSC, expressed as the 
percentage of total MNCs, with n = 8–9/group. The right panel shows dot plots of ASC positive splenocytes of 
control, CVB3, control MSC, and CVB3 MSC mice, as indicated. (B) Bar graphs represent the mean ± SEM 
of F4/80+/ASC+ in control mice (open bar) and CVB3-infected mice (closed bar) injected with PBS or MSC, 
expressed as the percentage of total MNCs, with n = 8–9/group and **p < 0.01. The right panel shows dot plots 
of F4/80+/ASC+- positive splenocytes of control, CVB3, control MSC, and CVB3 MSC mice, as indicated. (C) 
Bar graphs represent the mean ± SEM of CD49b+/ASC+ in control mice (open bar) and CVB3-infected mice 
(closed bar) injected with PBS or MSC, expressed as the percentage of total MNCs, with n = 8–9/group and 
**p < 0.01. The right panel shows dot plots of CD49b+/ASC+-positive splenocytes of control, CVB3, control 
MSC, and CVB3 MSC mice, as indicated. (D) Bar graphs represent the mean ± SEM of CD11c+/ASC+ in 
control mice (open bar) and CVB3-infected mice (closed bar) injected with PBS or MSC, expressed as the 
percentage of total MNCs, with n = 8–9/group and **p < 0.01. The right panel shows dot plots of CD11c+/
ASC+-positive splenocytes of control, CVB3, control MSC, and CVB3 MSC mice, as indicated.
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Results
Mesenchymal stromal cells inhibit NOD2 expression and NLRP3 inflammasome activation in 
the heart of Coxsackievirus B3-infected mice. To investigate the effects of MSC on NLRP3 inflam-
masome activation, one million MSC were i.v. injected one day post CVB3 infection in C57BL/6 mice. CVB3 
infection induced prominent NOD2 expression and NLRP3 inflammasome activation in the heart, as indicated 
by a 2.3-fold (p < 0.05) and 8.8-fold (p < 0.005) increase in LV NOD2 and NLRP3 mRNA expression, respectively. 
In parallel, CVB3 mice exhibited a 1.9-fold (p < 0.05), 6.5-fold (p < 0.005), 1.7-fold (p = 0.22), and 14.0-fold 
(p < 0.001) upregulated LV expression of ASC, caspase 1, IL-1β and IL-18, respectively (Fig. 1A–F). Importantly, 
MSC application in CVB3-infected mice not only reduced the LV expression of NOD2 by 2.7-fold (p < 0.05) 
Figure 5. Mesenchymal stromal cells abrogate Coxsackievirus B3-induced Caspase 1 p10 induction in 
macrophages, natural killer cells, and dendritic cells. (A) Bar graphs represent the mean ± SEM of p10 positive 
splenocytes in control mice (open bar) and CVB3-infected mice (closed bar) injected with PBS or MSC, 
expressed as the percentage of total MNCs, with n = 8–9/group. The right panel shows dot plots of p10 positive 
splenocytes of control, CVB3, control MSC, and CVB3 MSC mice, as indicated. (B) Bar graphs represent the 
mean ± SEM of F4/80+/p10+ in control mice (open bar) and CVB3-infected mice (closed bar) injected with 
PBS or MSC, expressed as the percentage of total MNCs, with n = 8–9/group, **p < 0.01 and ***p < 0.001. 
The right panel shows dot plots of F4/80+/p10+ positive splenocytes of control, CVB3, control MSC, and CVB3 
MSC mice, as indicated. (C) Bar graphs represent the mean ± SEM of CD49b+/p10+ in control mice (open bar) 
and CVB3-infected mice (closed bar) injected with PBS or MSC, expressed as the percentage of total MNCs, 
with n = 8–9/group and ***p < 0.001. The right panel shows dot plots of CD49b+/p10+ positive splenocytes 
of control, CVB3, control MSC, and CVB3 MSC mice, as indicated. (D) Bar graphs represent the mean ± SEM 
of CD11c+/p10+ in control mice (open bar) and CVB3-infected mice (closed bar) injected with PBS or MSC, 
expressed as the percentage of total MNCs, with n = 8–9/group, *p < 0.05 and **p < 0.01. The right panel 
shows dot plots of CD11c+/p10+-positive splenocytes of control, CVB3, control MSC, and CVB3 MSC mice, as 
indicated.
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and NLRP3 by 10.6–fold (p < 0.005), but also of ASC, caspase 1, IL-1β, and IL-18 by 2.1-fold (p < 0.01), 4.3-fold 
(p < 0.005), 3.8-fold (p < 0.05) and 8.2-fold (p < 0.005), respectively versus CVB3 mice. Furthermore, immuno-
histochemical analysis showed a significant 6.6-fold (p < 0.001) upregulation in ASC expression in the heart of 
CVB3-infected mice versus control mice (Fig. 1G and H). MSC treatment of CVB3 mice prominently downreg-
ulated the LV ASC protein expression by 4.5-fold (p < 0.001) versus CVB3 mice. NLRP3 inflammasome compo-
nents downstream of ASC remained unchanged as shown by unaltered LV caspase 1 activity (Fig. 1I), and IL-1ß 
protein expression (Fig. 1J) in CVB3-infected compared to control mice and they remained unaffected by MSC 
application.
Figure 6. Mesenchymal stromal cells suppress Coxsackievirus B3-induced IL-1β secretion by macrophages, 
natural killer cells, and dendritic cells. (A) Bar graphs represent the mean ± SEM of IL-1β-positive splenocytes 
in control mice (open bar) and CVB3-infected mice (closed bar) injected with PBS or MSC, expressed as the 
percentage of total MNCs, with n = 8–9/group and *p < 0.05. The right panel shows dot plots of IL-1β-positive 
splenocytes of control, CVB3, control MSC, and CVB3 MSC mice, as indicated. (B) Bar graphs represent the 
mean ± SEM of F4/80+/IL-1β+ in control mice (open bar) and CVB3-infected mice (closed bar) injected with 
PBS or MSC, expressed as the percentage of total MNCs, with n = 8–9/group and ***p < 0.001. The right 
panel shows dot plots of F4/80+/IL-1β+ positive splenocytes of control, CVB3, control MSC, and CVB3 MSC 
mice, as indicated. (C) Bar graphs represent the mean ± SEM of CD49b+/IL-1β+ in control mice (open bar) 
and CVB3-infected mice (closed bar) injected with PBS or MSC, expressed as the percentage of total MNCs, 
with n = 8–9/group, **p < 0.01 and ***p < 0.001. The right panel shows dot plots of CD49b+/IL-1β+ positive 
splenocytes of control, CVB3, control MSC, and CVB3 MSC mice, as indicated. (D) Bar graphs represent the 
mean ± SEM of CD11c+/IL-1β+ in control mice (open bar) and CVB3-infected mice (closed bar) injected with 
PBS or MSC, expressed as the percentage of total MNCs, with n = 8–9/group and ***p < 0.001. The right panel 
shows dot plots of CD11c+/IL-1β+-positive splenocytes of control, CVB3, control MSC, and CVB3 MSC mice, 
as indicated.
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Mesenchymal stromal cells suppress NOD2 expression and NLRP3 inflammasome activa-
tion in Coxsackievirus B3-infected cardiomyocytes. In parallel to the in vivo MSC effect on NOD2 
expression and NLRP3 inflammasome activation, the effect of MSC on NOD2 expression and NLRP3 inflam-
masome activation was evaluated in vitro in CVB3-infected HL-1 cardiomyocytes. MSC were added in a direct 
co-culture system for 4 hours to CVB3-infected Dil- or DiO-labeled HL-1 cardiomyocytes. NOD2, ASC and 
Figure 7. Mesenchymal stromal cells application in Coxsackievirus B3-infected mice improves the expression 
of genes important for cardiac contractility and fibrosis. Bar graphs represent the mean ± SEM of (A) SERCA2, 
(B) phospholamban, (C) Col1a1, (D) Col3a1, (E) LOX1 and (F) LOXL2 mRNA expression in the LV of control, 
CVB3, control MSC, and CVB3 MSC mice, as indicated, with n = 5–6/group and *p < 0.05, **p < 0.01, 
***p < 0.001, and ****p < 0.0001.
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caspase 1 were 1.6-fold (p < 0.01), 1.7-fold (p < 0.001) and 1.6-fold (p < 0.0001) increased in CVB3-infected 
HL-1 cells, respectively (Fig. 2A–C). Importantly, MSC supplementation decreased NOD2- and ASC-positive 
CVB3-infected HL-1 cells by 1.4-fold (p < 0.05) and 1.9-fold (p < 0.0005), respectively, and diminished the down-
stream caspase 1 expression by 1.3-fold (p < 0.001) compared to CVB3-infected HL-1 cells. Consistent with the 
reduction in caspase-1 expression in HL-1 cells co-cultured with MSC, the conversion of pro-IL-1β to IL-1β 
declined by 1.9-fold (p < 0.0001) in CVB3-infected HL-1 cells treated with MSC (Fig. 2E), while the percentage 
of pro-IL-1β on its own remained unchanged in all conditions (Fig. 2D). This finding demonstrates that MSC 
suppress CVB3-induced NLRP3 inflammasome activation and IL-1β production in cardiomyocytes.
We have previously demonstrated that MSC exert protective effects in viral myocarditis via release of para-
crine factors18. Oh et al.20 have recently shown that MSC efficiently inhibit NLRP3 inflammasome activation in 
macrophages via secretion of the anti-oxidative protein stanniocalcin (STC-1). Based on this finding and the 
relevance of oxidative stress in NLRP3 activation21, we next investigated the potential contribution of STC-1 
in the observed MSC inhibitory effect on CVB3-induced NLRP3 inflammasome activation in HL-1 cells. MSC 
transfection with STC-1 siRNA decreased STC-1 expression in MSC by 33% (Supplemental Fig. 1A), which was 
translated in a modest abrogation of the inhibitory effects of MSC on NLRP3 inflammasome activity in HL-1. 
This follows from the observation that the % of Dil/ASC/IL-1β-positive HL-1 cells was 1.2-fold (p < 0.05) higher 
in HL-1 cells co-cultured with STC-1 siRNA-transfected MSC compared to HL-1 cells co-cultured with scram-
bled siRNA-transfected MSC (Supplemental Fig. 1B).
To study whether MSC have an effect on inflammasome activation triggered in a classical manner, we primed 
HL-1 cells with lipopolysaccharide (LPS) followed by adenosine-triphosphate (ATP) supplementation, which 
led to an increase in inflammasome activation in HL-1 cells, as evident by a 1.2-fold (p < 0.001) increase in 
IL-1β- and ASC-double positive HL-1 cells (Supplemental Fig. 2). Supplementation of MSC at the time of LPS 
Figure 8. Hypothetical scheme of the effect of MSC application on NLRP3 inflammasome activation in the 
heart and innate immune cells of Coxsackievirus B3-infected mice. MSC application abrogates the expression 
of NOD2 and NLRP3 inflammasome components NLRP3, ASC, caspase 1 and IL-1β and IL-18 in the 
heart of CVB3-infected mice. The inhibitory effect of MSC on CVB3-induced inflammasome activation in 
cardiomyocytes was confirmed in vitro as indicated by a reduction in NOD2-, ASC-, and caspase 1-positve 
CVB3-infected cardiomyocytes and subsequent decrease in IL-1β secretion in the presence of MSC. MSC 
application mediated a systemic immunoregulation by suppressing NOD2 expression, inhibiting NLRP3 
inflammasome activation and IL-1β secretion by macrophages, natural killer cells, and dendritic cells. MSC 
exert inhibitory effects on NLRP3 inflmmasome activation presumably partly via suppressing NOD2 expression 
and partly via secretion of the paracrine factor STC-1. MSC application is an effective strategy abrogating 
NLRP3 inflammasome activation and preventing the adverse consequences of excessive myocardial and 
systemic inflammation. All MSC-mediated effects are marked with a red arrow. STC-1 is marked as a red bullet.
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priming or at the time of ATP treatment both prominently suppressed the inflammasome formation as evident by 
a 1.5-fold (p < 0.0001) and 2.6-fold (p < 0.0001) decrease in IL-1β- and ASC-double positive HL-1 cells, respec-
tively (Supplemental Fig. 2).
Mesenchymal stromal cells suppress Coxsackievirus B3-induced NOD2 expression in mac-
rophages, natural killer cells, and dendritic cells. Since NLRP3 is a downstream target of NOD24 and 
a major pathogenic mediator of cardiac inflammation and dysfunction in CVB3-induced myocarditis13, we next 
investigated the effect of MSC treatment on NOD2 expression in splenic macrophages (F4/80), natural killer 
(NK) cells (CD49b) and DCs (CD11c) upon CVB3 infection. Splenocytes were isolated from control, control 
MSC, CVB3, and CVB3 MSC mice and NOD2 expression in these different immune cells populations was sub-
sequently evaluated by flow cytometry. The total splenocytes fraction showed a 1.1-fold (p < 0.0001) increase in 
NOD2 expression upon CVB3 infection (Fig. 3A). In parallel, NOD2 expression was upregulated in macrophages 
(F4/80) and DCs (CD11c) upon CVB3 infection as indicated by a 1.2-fold (p < 0.0001) and 1.1-fold (p < 0.005) 
higher percentage of NOD2-positive macrophages (F4/80), and DCs (CD11c) in comparison to control mice, 
respectively. Importantly, MSC treatment of CVB3 mice decreased the percentage of NOD2-expressing mac-
rophages (F4/80), NK cells (CD49b) and DCs (CD11c) by 1.2-fold (p < 0.0001), 1.1-fold (p < 0.0001) and 1.2-fold 
(p < 0.0001), respectively (Fig. 3B–D).
Mesenchymal stromal cells inhibit Coxsackievirus B3-induced ASC activation in macrophages, 
natural killer cells, and dendritic cells. Considering the importance of ASC, which interacts with 
pro-caspase-1 via a CARD domain resulting in activation and maturation of caspase-1 and production of IL-1β, 
spleen MNCs were prepared from control, control MSC, CVB3, and CVB3 MSC mice and stained for ASC by 
flow cytometry. Regulation of the ASC activation was not detected when total splenocytes fraction were evaluated 
(Fig. 4A). However, specific immune cell subsets showed increased intracellular expression of ASC. ASC activa-
tion was induced in macrophages (F4/80), NK cells (CD49b) and DCs (CD11c) upon CVB3 infection as indicated 
by a 1.7-fold (p < 0.01) higher percentage of ASC in macrophages (F4/80), NK cells (CD49b) and DCs (CD11c) 
in comparison to control mice. In contrast, CVB3 MSC mice exhibited 1.8-fold (p < 0.01), 1.7-fold (p < 0.01) and 
1.7-fold (p < 0.05) lower ASC positive macrophages, NK cells and DCs (Fig. 4B–D).
Mesenchymal stromal cells decrease caspase-1 p10 expression in splenic macrophages, natu-
ral killer, and dendritic cells of Coxsackievirus B3-infected mice. Spleen cells derived from control, 
control MSC, CVB3 and CVB3 MSC mice were evaluated for caspase-1 expression by measuring the intracellular 
levels of cleaved caspase-1 p10 subunit by flow cytometry, as a measure of caspase-1 activation. The quantifi-
cation and the FACS dot plots shown in Fig. 5A illustrate no difference between the groups in caspase-1 p10 
expression in the total population of spleen cells. However, CVB3-infection increased the intracellular levels 
of the cleaved caspase-1 p10 subunit in macrophages (F4/80), NK cells (CD49b) and DCs (CD11c) by 1.7-fold 
(p < 0.01), 1.9-fold (p < 0.0001) and 1.4-fold (p < 0.01), respectively, in comparison with control mice. In parallel 
with the effect of MSC on the initiation of NLRP3 inflammasome activation, MSC application decreased down-
stream p10 expression in splenic macrophages (F4/80), NK cells (CD49b), and DCs (CD11c) by 1.8-fold, 1.7-fold 
and 1.4-fold, respectively (Fig. 5B–D).
Mesenchymal stromal cells abrogate secretion of IL-1β in splenic macrophages, natural killer, 
and dendritic cells of Coxsackievirus B3-infected mice. IL-1β is a potent pro-inflammatory cytokine, 
which induces the synthesis and expression of several hundreds of secondary inflammatory mediators and it is a 
key mediator of the systemic inflammatory response in heart failure, having a direct cardio-depressive effect10,11. 
Spleen MNCs from CVB3-infected mice had 1.8-fold (p < 0.05) higher IL-1β expression compared to spleen 
MNC from controls (Fig. 6A). In parallel, IL-1β in splenic macrophages (F4/80), NK cells (CD49b) and DCs 
(CD11c) was 2.8-fold (p < 0.0001), 2.0-fold (p < 0.01), and 2.9-fold ( < 0.0001) higher in comparison to con-
trol mice (Fig. 6B–D). MSC application in CVB3 infected mice diminished the IL-1β releasing spleen MNCs 
by 2.1-fold (p < 0.05) as well as IL-1β in splenic macrophages (F4/80), NK cells (CD49b) and DCs (CD11c) by 
2.4-fold (p < 0.0001), 1.9-fold (p < 0.01), and 2.1-fold (p < 0.001) (Fig. 6A–D), respectively.
To investigate the effect of MSC on classically triggered NLRP3 inflammasome activation and IL-1β secre-
tion by splenic macrophages (F4/80), NK cells (CD49b) and DCs (CD11c), splenocytes from control mice were 
left untreated or primed with LPS and stimulated with ATP in the presence or absence of MSC. After 24 h of 
co-culture, splenocytes were collected and flow cytometry analysis was performed. LPS and ATP stimulation 
increased IL-1β-positive macrophages (F4/80), NK cells (CD49b) and DCs (CD11c) by 1.3-fold (p < 0.0001), 
1.4-fold (p < 0.0001), and 1.2-fold (p < 0.0001), respectively. MSC induced a general suppressive effect on the 
LPS- and ATP-triggered IL-1β secretion of macrophages (F4/80), NK cells (CD49b) and DCs (CD11c) as evident 
by a 1.7-fold (p < 0.0001), 1.9-fold (p < 0.0001), and 1.5-fold (p < 0.0001) reduction in IL-1β secretion, respec-
tively (Supplemental Fig. 3).
Mesenchymal stromal cells application in Coxsackievirus B3-infected mice normalize the gene 
expression of regulators of cardiac contractility and fibrosis. Elevated IL-1β and IL-18 expression is 
associated with impairment of cardiac function, as shown by altered sarco/endoplasmic reticulum Ca2+-ATPase 
(SERCA2) and phospholamban expression8 and upregulated pro-fibrotic LOX22. Taking this link into account, we 
evaluated the LV expression of SERCA2, phospholamban, LOX1 and LOXL2, critical regulators of cardiac con-
tractility and fibrosis, respectively, as well as of col1a1 and col3a1. CVB3 infection induced a 1.7-fold (p < 0.05) 
downregulation in SERCA and a 2.5-fold (p < 0.01) upregulation of phospholamban LV mRNA expression 
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(Fig. 7A and B). MSC application in CVB3-infected mice positively regulates the gene expression of critical genes 
responsible for the cardiac contractility, as evident by a 1.6 fold (p < 0.05) upregulation in LV SERCA expres-
sion and a 3.8-fold (p < 0.001) downregulation in LV phospholamban expression in CVB3-infected mice treated 
with MSC versus CVB3 mice (Fig. 6A and B), respectively. In parallel, CVB3-infected mice exhibited 3.9-fold 
(p < 0.001), 5.2-fold (p < 0.001), 18-fold (p < 0.0001), and 2.6-fold (p < 0.01) higher LV col1a1, col3a1, LOX1 and 
LOXL2 mRNA expression, respectively, while MSC injection in CVB3 mice led to a 1.7-fold (p = 0.074), 5.1-fold 
(p < 0.001), 9.0-fold (p < 0.0005), and 2.9-fold (p < 0.005) lower LV col1a1, col3a1, LOX1, and LOXL2 mRNA 
expression, respectively (Fig. 7C–F).
The associations between cardiac contractility/cardiac fibrosis parameters and NLRP3 infammasome activa-
tion is shown by linear regressions (Supplemental Fig. 4).
Discussion
MSC application suppresses NOD2 and NLRP3 inflammasome gene expression and prevents the NLRP3 inflam-
masome assembly by downregulating the ASC protein expression in the heart of the CVB3-infected mice. 
Moreover, the present study extends the knowledge about the systemic immunomodulatory effects of MSC in 
myocarditis, showing that MSC abrogate the expression of NOD2, NLRP3 inflammasome activation and subse-
quent IL-1β production in macrophages (F4/80), NK cells (CD49b) and DCs (CD11c) of CVB3-infected mice. 
The suppressive effect of MSC on NOD2 expression and NLRP3 inflammasome activation is translated into 
normalized expression of important genes of cardiac contractility and fibrosis, which could potently abrogate 
the development of adverse cardiac dysfunction and remodelling following viral-induced myocardial injury. We 
suggest that the inhibitory effects of MSC on NLRP3 inflammasome activation is mediated at least partly via 
suppression of NOD2 expression and via secretion of anti-oxidative STC-1.
NLRP3 inflammasome activation is detected in heart biopsy samples of acute myocarditis patients and post-
mortem cases of myocarditis of unknown etiology23 and plays a leading role in the pathogenesis of myocarditis12. 
NLRP3 activation can be due to NLRP3 priming, i.e. induction of NLRP3 mRNA expression involving NF-kB 
or upstream NOD2, or due to direct activation of the NLRP3 inflammasome via mediators like reactive oxygen 
species (ROS) and ATP4. NOD2 is a cytoplasmatic PRR, which recognizes ssRNA, including CVB35 and activates 
NLRP3 inflammasome and IL-1β processing and secretion4. Our recent findings reveal that NOD2 is a major 
mediator in the pathogenesis of CVB3-induced myocarditis13. We showed that NOD2 expression was upregu-
lated in endomyocardial biopsies of CVB3-positive patients. Furthermore, cardiac NOD2 and NLRP3 expression 
dropped in CVB3-positive patients who eliminated the virus and improved cardiac function over time13. The rele-
vance of NOD2 expression in CVB3 myocarditis further followed from NOD2−/− CVB3 mice which were rescued 
from the detrimental effects of CVB3. They exhibited a minor inflammatory response, lower cardiac fibrosis and 
decreased NLRP3 activation. It should be noted however that the NOD2 expression was not increased in patients 
with a persistence of the cardiotropic viruses parvovirus B19 or human herpesvirus 6 (HHV-6) type B, which are 
among the most frequently found cardiotropic viruses in endomyocardial biopsies24–26, whereas its regulation in 
primarily autoimmune myocarditis still needs to be investigated. Our present findings which indicate a potent 
inhibitory effect of MSC on cardiac CVB3-induced NOD2 gene expression might therefore only be limited to the 
pathology of CVB3-induced myocarditis, and not generalized for all myocarditis etiologies. MSC further reduced 
the gene expression of all NLRP3 inflammasome components and products, which relevance has been shown in 
different cardiovascular disorders besides myocarditis11,27. Only ASC protein level was markedly increased in the 
heart of CVB3-infected mice and downregulated by MSC, while at this time point, cardiac caspase 1 activity and 
IL-1ß protein expression remained unchanged upon CVB3 infection and were not affected by MSC application. 
Interestingly, see supra, caspase 1 and IL-1ß protein expression was already increased in splenic macrophages, NK 
cells and DCs of those CVB3-infected versus control mice. The observed discrepancy in caspase 1 and IL-1β pro-
tein expression in the heart and the spleen at the same time point probably reflects a difference in the basal expres-
sion of NLRP3 inflammasome and in the mechanism of inflammasome activation. Tissue resident cells may not 
need to respond to injurious/infectious agents as promptly as cells of the innate immune response. Indeed, the 
mechanism of inflammasome regulation has been shown to be tissue-specific as NLRP3 expression in the heart 
of wildtype mice is lower than that in the spleen28. Nevertheless, the upregulated LV protein expression of ASC in 
CVB3-infected mice indicates already initiation of NLRP3 inflammasome formation4 in the heart of myocarditis 
mice, which could be decreased via MSC application. The suppressive effect of MSC on NOD2, NLRP3 inflam-
masome and IL-1β expression was confirmed in vitro in CVB3-infected cardiomyocytes. MSC supplementation 
abolished not only the CVB3-induced ASC protein expression and NLRP3 assembly, but also the downstream 
caspase 1 expression and conversion of pro-IL-1β to active IL-1β in CVB3-infected HL-1 cells.
ROS are a central and common upstream cellular signal triggering NLRP3 inflammasome activation21. The 
intracellular oxidation status has been implicated in the pathogenesis of CVB3 infections29. Moreover, Wang et al.12  
showed that the production of ROS is crucial for inflammasome activation in response to CVB3 infection. 
Importantly, we have previously demonstrated that MSC reduce the CVB3-induced ROS production in cardi-
omyocytes18, whereas Oh et al.20 recently illustrated that MSC decrease mitochondrial ROS and inhibit LPS- 
and ATP-induced NLRP3 inflammasome activation in macrophages primarily by secreting STC-1. Based on 
these findings, we wanted to understand if MSC negatively regulate the NLRP3 inflammasome activation in 
CVB3-infected HL-1 cells in an STC-1-dependent manner. Therefore, we knocked down STC-1 in MSC and sub-
sequently co-cultured them with CVB3-infected HL-1 cardiomyocytes. The partial knockdown of STC-1 in MSC 
modestly abrogated the inhibitory effect on NLRP3 activation in cardiomyocytes (Supplemental Fig. 1) suggest-
ing that MSC mediate their effect at least partly in an STC-1-dependent manner. Furthermore, we demonstrated 
that MSC reduce LPS- and ATP-triggered NLRP3 inflammasome activity in HL-1 cardiomyocytes, indicating that 
the inhibitory effect on the NLRP3 inflammasome is not solely restricted to CVB3 as a trigger, a finding which 
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could also be confirmed in splenic macrophages, NK cells, and DCs. Taken together the discussed findings sug-
gest that MSC suppress NLRP3 inflammasome activation presumably via reduction of NOD2 expression, ROS 
production and release of paracrine factors, such as the anti-oxidative factor STC-1.
Aside of the direct cardiac injury in CVB3-induced myocarditis30, inflammation is the leading component 
and the dominant mechanism in the pathogenesis of viral myocarditis1. MSC have been shown to inhibit NLRP3 
inflammasome activation in vitro in macrophages20. In the present study, we could demonstrate that MSC medi-
ate an effective systemic immunoregulation in viral myocarditis via reduction of NOD2 expression and abroga-
tion of NLRP3 inflammasome activation in macrophages (F4/80), NK cells (CD49b) and DCs (CD11c). NOD2 
activation in inflammatory cells may induces NF-κB and MAPK signalling pathways triggering a cell signaling 
cascade enhancing the secretion of pro-inflammatory immune factors - TNF-α, IL-6, CCL2, IL-8 -31, which affect 
signaling molecules in cardiac residential cells ultimately resulting in cardiac injury. NOD2 induces the pro-
duction of CC-chemokine ligand 2 (CCL2) and helps to drive the recruitment and priming of innate immune 
cells, including neutrophils and inflammatory Ly6Chi monocytes32. Importantly, we have recently demonstrated 
that MSC attenuate myocardial inflammation via suppression of the cardiac infiltration of Ly6Chi pro‐inflamma-
tory monocytes in CVB3-induced myocarditis33. Furthermore, NOD2 supports the recruitment of inflammatory 
macrophages34, known to mediate deteriorating immune overreaction as depletion of macrophages significantly 
improve both acute and chronic viral myocarditis, further confirming the critical pathological role of mac-
rophages in CVB3-induced myocarditis35. Macrophages are the most abundant cells in the inflamed myocardium 
of CVB3-infected mice and induce the expression of IL-1β, promoting cardiac inflammation, cardiac dilatation, 
fibrosis and heart failure36. Therefore, we assume that the suppressive effect of MSC on NLRP3 inflammasome 
activation and IL-1β secretion by macrophages could be beneficial in viral myocarditis preventing disease pro-
gression to cardiac dilatation and heart failure. DCs infiltrate the myocardium and release a cocktail of proinflam-
matory cytokines and induce CD4+ T-cell-mediated autoimmune induction in experimental CVB3 myocarditis37. 
MSC inhibit the NLRP3 inflammasome activation and IL-1β release by DCs, which might prevent autoimmunity 
induction. Given the significant involvement of autoimmune mechanisms in both experimental38,39 and human40 
myocarditis and the finding that excessive inflammasome activation can cause autoimmune disorders41, these 
inhibitory effects of MSC on inflammasome activation could have major implications on autoimmune reactivity 
in CVB3 myocarditis which could subsequently lead to an improvement in chronic myocarditis pathology.
The NK cells not only control the virus replication42, but also release perforin in CVB3-induced myocarditis43. 
MSC inhibit the NLRP3 inflammasome activation and IL-1β released by NK cells, limiting the long-term NK cells 
activation and release of cytotoxic factors which could damage myocytes in absence of significant virus titers in 
the heart tissue.
IL-1β levels strongly correlate with the severity of CVB3-induced myocarditis12. MSC treatment in CVB3 
mice downregulated LV mRNA expression of IL-1β and IL-18, which both induce cardiodepressive effects in 
heart failure10,11 and alter phospholamban expression, a key regulator of cardiac contractility8. Blockade of IL-1β 
or neutralization of IL-18 is an effective cardioprotective approach10,44. Therefore, the inhibitory effect of MSC 
on LV IL-1β and IL-18 gene expression and IL-1β-expressing splenic macrophages, NK cell, and DCs could have 
beneficial cardiac therapeutic implications.
In agreement with the previously demonstrated anti-fibrotic and cardioprotective effects of MSC, associ-
ated with improved LV function in CVB3-infected myocarditis mice as demonstrated via conductance hemo-
dynamic measurments18,19, we now show in the same experimental setting that the MSC inhibitory effect on 
NOD2 and NLRP3 inflammasome activation is associated with an improved expression of markers involved in 
Ca2+ regulation (SERCA, phospholamban) and cardiac fibrosis (col3a1, LOX1, LOXL2). Decreased expression 
levels of SERCA and a lower ratio of SERCA to its endogenous modulator phospholamban in the heart results in 
decreased contractility45, whereas LOX enzymes are key players in extracellular matrix deposition, maturation 
and cross-linking of collagen fibrils, which leads to myocardial stiffness, left ventricular dysfunction, and heart 
failure46,47. Moreover, we found a strong correlation between LV NLRP3 and phospholamban, col3a1, LOX1, and 
LOXL2 mRNA expression (Supplemental Fig. 4). These observations further support and clarify that i.v. MSC 
application improves LV function (contractility, stiffness) in CVB3 myocarditis mice via reducing cardiac fibrosis 
(collagen and crosslinking) and via modulating the expression of proteins involved in Ca2+ regulation.
In summary, the present study demonstrates that MSC are potent regulators of the NLRP3 inflammasome in 
the heart and in innate immune cells. MSC decrease NLRP3 activity, presumably from the combined reduction 
in NOD2 expression and the decrease in NLRP3 inflammasome activity involving the paracrine factor STC-1 
(Fig. 8). Therefore, MSC application could be a promising strategy to hamper the NLRP3 inflammasome acti-
vation limiting the adverse consequences of excessive myocardial and systemic inflammation associated with 
abnormal expression of genes regulators of cardiac contractility and fibrosis.
Methods
Murine Coxsackievirus B3-induced myocarditis and cell application. Eight-week-old male C57BL/6 
mice were infected by intraperitoneal injection of 1 × 105 plaque forming units (PFU) of CVB3 virus (Nancy 
strain). Control mice received PBS instead of CVB3. One day after CVB3 virus infection, 1 × 106 MSC were i.v. 
administrated via the tail vein into C57BL/6 mice. All mice were sacrificed on day seven post-CVB3 infection. 
The LV was harvested and snap-frozen for molecular biology. For flow cytometry analysis, heart, blood, and 
spleen mononuclear cells (MNCs) were isolated. The investigation was approved by the local ethical committee 
(Landesamt für Gesundheit und Soziales, Nr: G0094/11) and was performed in accordance with the European 
principles of laboratory animal care (Directive 2010/63/EU) and German animal protection law.
Mesenchymal Stromal Cell Isolation. Human adult MSC were isolated from iliac crest bone marrow 
aspirates of 8 healthy donors after their written approval according to Binger et al.48 MSC were cultured and 
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expanded for injection in Dulbecco’s Modified Eagle’s Medium (Biochrom, Berlin, Germany) supplemented with 
10% fetal bovine serum (FBS), 1% penicillin/streptomycin, 1% glutamine, 2% HEPES, and 2 ng/mL of basic fibro-
blast growth factor (Tebu-bio, Offenbach, Germany). Cultivated MSC were triple negative for the markers CD45, 
CD34, and CD11b, but stained positively for the markers CD73, CD29, CD105, CD106, CD90, and CD44.
Spleen mononuclear cell isolation and flow cytometry analysis. Splenocytes were isolated from 
control PBS, control MSC, CVB3 and CVB3 MSC mice according to Van Linthout et al.18. All samples were 
pre-incubated with FcR block Ab and flow cytometry analysis of spleen MNCs was performed using directly 
conjugated monoclonal mouse antibodies: anti-mouse F4/80 Pacific Blue (BM8), anti-mouse CD49b PerCP/
Cy5.5 (DX5), CD11c APC (N418) or CD11c PE (N418), (Biolegend San Diego, CA, USA). Surface staining was 
performed according to the manufacturer’s instructions. IL-1β in spleen MNCs was measured after 12 h incuba-
tion with 50 ng/ml phorbol myristate acetate (PMA) and 500 ng/ml ionomycin in the presence of BD GolgiStop™ 
Protein Transport Inhibitor (BD Biosciences, Franklin Lakes, NJ, USA). For intracellular staining, the MNCs 
were fixed and permeabilized for 20 min at 4 °C with Cytoperm/Cytofix (BD Biosciences, Franklin Lakes, NJ, 
USA) and stained with anti-mouse NOD2 APC (R&D Systems Europe Ltd., Abingdon, OX14 3NB, United 
Kingdom), anti-mouse IL-1β APC (Monoclonal Rat IgG2B Clone #166931) (R&D Systems, Minneapolis, MN, 
USA), caspase-1 p10 Alexa Fluor 488 (Antibodies online, Atlanta, GA, USA) and ASC PE (Biolegend, San Diego, 
CA, USA) antibodies in BD Perm/Wash solution according to the manufacturer’s instructions. Sample analysis 
was performed on a MACSQuant Analyzer (Miltenyi Biotec, Bergisch Gladbach, Germany) and flow cytometry 
data were analyzed with FlowJo 8.7. software (FlowJo, LLC, RO, USA).
Gene expression analysis. Frozen murine heart tissue was homogenized with an IKA T25D ULTRA 
TURRAY homogenisator (Laboratory equipment, Germany) in Trizol, followed by chloroform extraction and 
isopropanol precipitation. MSC were collected 48 h post siRNA transfection in Trizol for RNA preparation. Next, 
RNA was DNase treated with the NucleoSpin RNA II Kit (Macherey-Nagel, Düren, Germany) and subsequently 
reverse transcribed via High Capacity cDNA Reverse Transcription Kit from Applied Biosystems by Thermo 
Fisher Scientific (Carlsbad, CA, USA). To assess the mRNA expression of the murine target genes NLRP3, ASC, 
caspase 1, IL-1β, IL-18, SERCA2, phospholamban, collagen 1 (col1a1), collagen 3 (col3a1), LOX, and LOXL2, and 
human stanniocalcin (STC)-1, mRNA expression was analyzed via real-time PCR using gene expression assays for 
NLRP3 Mm00840904_m1, ASC Mm00445747_g1, caspase 1 Mm00438023_m1, IL-1β Mm00434228_m1, IL-18 
Mm00434225_m1, SERCA2 Mm01201431_m1, phospholamban Mm04206542_m1, col1a1 Mm01302043_g1, 
col3a1 Mm00802331_m1, LOX Mm00495386_m1 and LOXL2 Mm00804740_m1, and STC-1 Hs00174970_m1 
from Applied Biosystems by Thermo Fisher Scientific (Carlsbad, CA, USA). Murine mRNA expression was nor-
malized to the housekeeping gene CDKN1b Mm00438167_g1 and relatively expressed with the control group set 
as 1. Human STC-1 was normalized to the housekeeping gene CDKN1b Hs00153277_m1 and relatively expressed 
with the control group set as 100%.
HL-1 and mesenchymal stromal cell co-culture experiments. Murine HL-1 cells were cultured in 
Claycomb medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% FBS, 1% penicillin/strepto-
mycin, 100 μM norepinephrine (Sigma-Aldrich, St. Louis, MO, USA) and 2 mM glutamine (Biochrom, Berlin, 
Germany) for CVB3 infection and LPS and ATP stimulation experiments. For both experiments, DiO- or 
Dil-labeled (Vybrant® DiO or DiL Cell-labeling solution, Applied Biosystems by Thermo Fisher Scientific, 
Carlsbad, CA, USA) HL-1 were plated into 6-well plates at a density of 250,000 cells/6-well for ASC, caspase 1, 
IL-1β or pro-IL-1β flow cytometry analysis, respectively.
For CVB3 infection experiments, DiO- or Dil-labeled HL-1 cells were 24 h after plating, serum starved or 
infected with CVB3 under serum starvation conditions at a m.o.i. of 4 for 1 h. Then, cells were washed with PBS 
two times and complete Claycomb medium was added. Untreated MSC or MSC 48 h after tranfection with 30 nM 
scrambled or stanniocalcin (STC-1) siRNA were collected and added to the HL-1 cells for co-culture at a ratio of 
MSC to HL-1 of 1 to 10, which is a commonly used ratio when MSCs are co-cultured in the presence of a target 
cell of interest18. Four h after infection, cells were collected for flow cytometry purposes.
For LPS and ATP stimulation experiments, DiO-labeled HL-1 cells were washed with PBS 24 h after plating 
and next stimulated with 25 ng/ml of LPS from Escherichia coli O55:B5 (Merck) for 2 h. Then, cells were washed 
twice with PBS and stimulated with 5 mM ATP for 1 h (Invivo Gen, San Diego, CA, USA). MSC were added for 
co-culture at a ratio of 1 MSC to 10 HL-1 at the timepoint of LPS or ATP administration. One h after ATP supple-
mentation, cells were collected for flow cytometry purposes.
Splenocytes and mesenchymal stromal cell co-culture experiments. MSC were plated at a den-
sity of 15,000 cells/96-well in complete MSC medium. Twenty-four h later, splenocytes from control mice were 
added at a ratio of 10 to 1 MSC in 90 µl of RPMI1640 medium supplemented with 10% FBS and 1% penicillin/
streptomycin with/out 25 ng/ml LPS (Merck). After 2 h, 0 or 10 µl of ATP was added to the LPS conditions at a 
final conc. of 5 mM, whereas to the other wells 10 µl of PBS was added. After 1 h, cells were fixed and permea-
bilized for 20 min at 4 °C with Cytoperm/Cytofix (BD Biosciences, Franklin Lakes, NJ, USA) and stained with 
anti-mouse F4/80 Pacific Blue (BM8), anti-mouse CD49b PerCP/Cy5.5 (DX5), CD11c APC (N418) or CD11c PE 
(N418) (Biolegend), anti-mouse ASC PE (Biolegend) and anti-mouse IL-1β APC (Monoclonal Rat IgG2B Clone 
#166931) (R&D Systems) antibodies in BD Perm/Wash solution according to the manufacturer’s instructions. 
Sample analysis was performed on a MACSQuant Analyzer (Miltenyi Biotec, Bergisch Gladbach, Germany) and 
flow cytometry data were analyzed with FlowJo 8.7. software (FlowJo, LLC, RO, USA).
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Flow cytometry analysis of NOD2, apoptosis-associated speck-like protein containing a CARD, 
IL-1β and pro-IL-1β. DiO-labeled HL-1 cells were infected with CVB3 and subsequently co-cultured with 
MSC as described above. Four hours post CVB3 infection, HL-1 cells were fixed in Fixation/Permeabilization 
solution (BD Biosciences, Franklin Lakes, NJ, USA) and stained with APC anti-NOD2 (R&D Systems Europe 
Ltd.), PE anti-ASC (TMS-1) (Biolegend San Diego, CA, USA), anti-mouse PerCP mIL-1β/IL-1F2 (R&D Systems, 
Minneapolis, MN, USA) or anti-mouse PE IL-1β pro-form (eBioscience, San Diego, CA, USA). Sample analysis 
was performed on a MACSQuant Analyzer (Miltenyi Biotec, Bergisch Gladbach, Germany) and flow cytometry 
data were analyzed with FlowJo 8.7. software (FlowJo, LLC, RO, USA). Data are presented as DiO+ASC+ cells (% 
of gated) or DiO+IL-1β+ (% of gated) or DiO+pro-IL-1β+ cells (% of gated), respectively.
Flow cytometry analysis of caspase 1. DiL-labeled HL-1 cells were infected with CVB3 and subse-
quently co-cultured with MSC as described above. Four hours post CVB3 infection HL-1 cells were collected and 
stained for flow cytometry analysis with Caspase-1 FAM-YVAD- FMK KIT (ImmunoChemistry Technologies, 
Bloomington, U.S.A.) according to the manufacturer’s instruction and washed with 1× Apoptosis Wash Buffer. 
Sample analysis was performed on a MACSQuant Analyzer (Miltenyi Biotec, Bergisch Gladbach, Germany) and 
flow cytometry data were analyzed with FlowJo 8.7. software (FlowJo, LLC, RO, USA). Data are presented as 
DiL+Caspase 1 cells+ (% of gated).
Immunohistology. Immunohistochemistry was carried out on 5 µm-thick cryosections using ASC (TMS-
1) antibody (GeneTex, CA, USA). Analysis of stained sections was made in a blinded fashion by digital image 
analysis on a Leica DZ 2000 LED microscope (Leica Microsystems, Wetzlar, Germay) at a 100× magnification.
Caspase-1 activity assay. LV caspase 1 activity was measured with a caspase-1 colorimetric assay (R&D 
Systems, Minneapolis, MN, USA) according to the manufacturer’s protocol. In brief, 50 µl of tissue lysate con-
taining 100 µg of LV protein extract of C57BL/6 control and CVB3-infected mice i.v. injected with MSC or PBS 
was mixed with 50 μl of 2X Reaction Buffer 1 and 5 μl of a caspase-1 colorimetric substrate and incubated for 
2 hours at 37 °C. The caspase 1 activity in the samples was quantified with a microplate reader using a wavelength 
of 405 nm. Data represent the absorbance of the samples.
IL-1β ELISA. Mouse cardiac IL-1β levels were determined in tissue lysate of LV protein extract (diluted 1:150, 
total volume 100 µl) of C57BL/6 control and CVB3-infected mice i.v. injected with MSC or PBS. A mouse IL-1β 
ELISA kit (Cloud Clone Corp., Houston, USA) was used according to the manufacturer’s protocol. IL-1ß concen-
trations were normalized to total LV protein concentrations.
siRNA experiments. MSC were transfected with siPORT™ Amine Transfection Agent (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA) with 30 nM of STC-1 or scrambled siRNA (Thermo Fisher Scientific) 
following the manufacturer’s protocol. Real-time PCR was performed to confirm knockdown of STC-1 
(Supplemental Fig. 1A).
Statistical analysis. Statistical analysis was performed using Prism 6 for Mac OS X (GraphPad Software, 
Inc., La Jolla, USA). Ordinary one-way ANOVA was used for statistical analysis of the data with correction for 
multiple comparisons via the Tukey test. Data are presented as mean ± SEM. Differences were considered to be 
significant when the two-sided p-value was lower than 0.05.
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